Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 114Terminated 50Recruiting 28Active not recruiting 24Unknown 15Withdrawn 14Not yet recruiting 3No longer available 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 3Colorectal Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Turcot syndrome 1Sarcoma 1Post-Acute COVID-19 Syndrome 1Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Advanced Kidney Cancer 1

Interventions

Nivolumab 6pembrolizumab 3Specimen Handling 3Ipilimumab 3relatlimab 2cemiplimab 2Melphalan 2Magnetic Resonance Spectroscopy 2Interleukin-2 2vedolizumab 1trametinib 1toripalimab 1sulforaphane 1gadopiclenol 1famitinib 1anlotinib 1X-Rays 1Watchful Waiting 1Ultraviolet Therapy 1Toll-Like Receptor 1 1Therapeutics 1Temozolomide 1Technetium 1Standard of Care 1Sentinel Lymph Node Biopsy 1SHR-1701 1Rehabilitation 1Phototherapy 1Photopheresis 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Melanoma × Ipilimumab × Clear all
NCT07511036 2026-04-06

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
20 enrolled
Dermatologic

Melanoma

NCT06683755 2024-11-12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Dermatologic

Melanoma

NCT02498756 2015-07-15

Cytokine-induced Killer Study for Patients With Stage II Melanoma

The First People's Hospital of Changzhou

Phase 2 Not yet recruiting
300 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡